| Literature DB >> 34926696 |
Ping Na Zhang1, Meng Qi Zhou1, Jing Guo1, Hui Juan Zheng1, Jingyi Tang1, Chao Zhang1, Yu Ning Liu1, Wei Jing Liu1,2, Yao Xian Wang1.
Abstract
Diabetic nephropathy (DN) is a progressive microvascular diabetic complication. Growing evidence shows that persistent mitochondrial dysfunction contributes to the progression of renal diseases, including DN, as it alters mitochondrial homeostasis and, in turn, affects normal kidney function. Pharmacological regulation of mitochondrial networking is a promising therapeutic strategy for preventing and restoring renal function in DN. In this review, we have surveyed recent advances in elucidating the mitochondrial networking and signaling pathways in physiological and pathological contexts. Additionally, we have considered the contributions of nontraditional therapy that ameliorate mitochondrial dysfunction and discussed their molecular mechanism, highlighting the potential value of nontraditional therapies, such as herbal medicine and lifestyle interventions, in therapeutic interventions for DN. The generation of new insights using mitochondrial networking will facilitate further investigations on nontraditional therapies for DN.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34926696 PMCID: PMC8677373 DOI: 10.1155/2021/1010268
Source DB: PubMed Journal: J Diabetes Res Impact factor: 4.011
Mitochondria-targeted herb medicine in DN.
| Herb medicine | The form of herb medicine | Experimental model | Target | Pathway | Observed effect | Ref. |
|---|---|---|---|---|---|---|
|
| ||||||
| Berberine | Pure chemical | Patients with DN, db/db diabetic mice | PCG-1 | PGC-1 | Restoration of PGC-1 | [ |
| Tangshen formula | Extract | db/db diabetic mice, mTECs | PGC-1 | PGC-1 | Improving cholesterol efflux | [ |
| Salidroside | Pure chemical | db/db diabetic mice | SIRT1↑, PGC-1 | SIRT1/PGC-1 | Improving mitochondrial biogenesis | [ |
| Resveratrol | Pure chemical | db/db diabetic mice, HGECs | AdipoR1↑, AdipoR2↑, AMPK↑, SIRT1↑, PGC-1 | AMPK–SIRT1–PGC–1 | Ameliorating lipotoxicity, oxidative stress, apoptosis, and endothelial dysfunction | [ |
| Resveratrol | Pure chemical | db/db diabetic mice | AMPK↑, SIRT1↑, PGC-1 | AMPK–SIRT1–PGC–1 | Prevention of lipotoxicity-related apoptosis and oxidative stress | [ |
| Resveratrol | Pure chemical | STZ-induced diabetic rats, podocytes | SIRT1↑, PGC-1 | SIRT1/PGC-1 | Inhibition of mitochondrial oxidative stress and apoptosis | [ |
| Resveratrol | Pure chemical | DN rabbits with AKI, HK-2 cells | SIRT1↑, PGC-1 | SIRT1–PGC–1 | Reducing renal hypoxia, mitochondrial dysfunction and renal tubular cell apoptosis | [ |
| Marein | Extract | db/db diabetic mice, HK-2 cells | SGLT2↓, SREBP-1↓, AMPK↑, PGC-1 | AMPK/ACC/PGC-1 | Amelioration of fibrosis and inflammation | [ |
|
| ||||||
| Berberine | Pure chemical | db/db diabetic mice, podocytes | DRP1↓, MFF↓, FIS1↓, MID49↓, MID51↓, PGC-1 | DRP1 modulator | Inhibiting mitochondrial fission and cell apoptosis | [ |
| Astragaloside IV | Pure chemical | db/db diabetic mice | Drp1↓, MFF↓, Fis1↓ | Mitochondrial quality control network | Amelioration of renal injury | [ |
| Polydatin | Pure chemical | KKAy mice, hyperglycemia-induced MPC5 cells | DRP1↓, ROS↓, caspase-3↓, caspase-9↓ | ROS/DRP1/mitochondrial fission/apoptosis pathway | Impairing mitochondria fitness and ameliorating podocyte injury | [ |
|
| ||||||
| Astragaloside II | Pure chemical | STZ-induced diabetic rats | NRF2↑, Keap1↓, PINK1↑, Parkin↑ | NRF2 and PINK1 pathway | Amelioration of podocyte injury and mitochondrial dysfunction | [ |
| Huangqi-Danshen decoction | Extract | db/db diabetic mice | DRP-1↓, PINK1↑, Parkin↑ | PINK1/Parkin pathway | Protection kidney injury by inhibiting PINK1/Parkin-mediated mitophagy | [ |
|
| ||||||
| Nepeta angustifolia C. Y. Wu | Extract | HFD/STZ-induced diabetic rats, mesangial cells | SOD↑, ROS↓, MDA↓ | Mitochondrial-caspase apoptosis pathway | Antioxidative stress, inflammation and inhibiting mesangial cell apoptosis | [ |
| Resveratrol | Pure chemical | db/db diabetic mice | ROS↓, AMPK↑, SIRT1 | AMPK/SIRT1-independent pathway | Antioxidative stress and enhanced mitochondrial biogenesis | [ |
| Betulinic acid | Pure chemical | STZ-induced diabetic rats | SOD↑, CAT ↑, MDA↓, AMPK, NF- | AMPK/NF- | Attenuating the oxidative stress and inflammatory condition | [ |
| Obacunone | Pure chemical | NRK-52E cells | SOD↑, GSK-3 | GSK-3 | Inhibiting oxidative stress and mitochondrial dysfunction | [ |
| Curcumin | Pure chemical | STZ-induced diabetic rats | NRF2↑, FOXO-3a↑, PKC | PKC | Antioxidative stress | [ |
| Notoginsenoside R1 | Pure chemical | db/db diabetic mice, HK-2 cells | ROS↓, NRF2↑, HO-1↑ | NRF2 pathway | Inhibition of apoptosis and renal fibrosis caused by oxidative stress | [ |
| Oleanolic acid and N-acetylcysteine | Pure chemical | Type 2 diabetic rat model, mesangial cells | ROS↓, NRF2↑, TGF- | NRF2/Keap1 system | Inhibition of oxidative stress and ER stress | [ |
Figure 1Hyperglycemia serves as the primary factor that influences mitochondrial dysfunction in DN. The increased level of glucose enhances glycolysis, and the subsequent activation of the TXNIP, AGE, and PKC pathways reinforces the decrease in ATP levels. Insufficient ATP levels stimulate the ETC to overwork in response to the energy supply for the kidneys. In turn, excessive ROS production occurs following the overactivation of the ETC, which results in decreased ATP production, mutation of mtDNA, abnormal opening of the mitochondrial permeability transition pore, and ultimately mitochondrial fragmentation and swelling. Decreases in the levels of OPA1, MFN1, and MFN2 may contribute to the decrease in mitochondrial fusion observed in DN. Activation of DRP1 promotes mitochondrial fragmentation and fission. Damaged mitochondria are cleared by mitophagy. However, an excess number of damaged mitochondria that is higher than the rate of mitophagy may result in cell death. Abbreviations: DN: diabetic nephropathy; DRP1: dynamin 1-like protein; PGC-1α: PGC1α, peroxisome proliferator-activated receptor γ coactivator 1α; AMPK: 5′-AMP-activated protein kinase; SIRT1: sirtuin-1; PINK1: putative kinase protein 1; Cyt c: cytochrome c; ROS: reactive oxygen species; MFN1 and 2: mitofusin proteins 1 and 2; OPA1: optic atrophy protein 1; MFF: mitofission proteins; FIS1: mitochondrial fission 1; PPAR: peroxisome proliferator-activated receptor; Parkin: E3 ubiquitin-protein ligase parkin; ER: endoplasmic reticulum; TXNIP: thioredoxin-interacting protein; AGE: advanced glycation end; PKC: protein kinase C; ETC: electron transport chain.
Figure 2Therapeutic target of herbal medicine on mitochondrial dysfunction in DN. Herbal medicine plays a protective role in inhibiting DRP1-mediated mitochondrial dynamics to improve mitochondrial dysfunction in DN. In addition, herbal medicine enhances mitochondrial biogenesis by inducing the expression of PGC-1α and its upstream regulators (AMPK and SIRT1) and drives PINK1/Parkin-mediated mitophagy. In addition, the renoprotective effects of herbal medicine are associated with antioxidative stress. Abbreviations: DN: diabetic nephropathy; DRP1: dynamin 1-like protein; PGC-1α: PGC1α, peroxisome proliferator-activated receptor γ coactivator 1α; AMPK: 5′-AMP-activated protein kinase; SIRT1: sirtuin-1; PINK1: putative kinase protein 1; Cyt c: cytochrome c; ROS: reactive oxygen species; MFN1 and 2: mitofusin proteins 1 and 2; OPA1: optic atrophy protein 1; MFF: mitofission proteins; FIS1: mitochondrial fission 1; PPAR: peroxisome proliferator-activated receptor; Parkin: E3 ubiquitin-protein ligase parkin.